NCT05862194View on ClinicalTrials.gov

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

CompletedOBSERVATIONAL
Enrollment

534

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

April 30, 2022

Study Completion Date

March 20, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Lazertinib

Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period

DRUG

Platinum-based Chemotherapy

Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT05862194 - Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC | Biotech Hunter | Biotech Hunter